Skip to main content
Figure 3 | Molecular Cancer

Figure 3

From: Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1α

Figure 3

Induction of apoptosis in cancer cells with wild-type EGFR or tyrosine kinase domain-mutated EGFR by cetuximab and gefitinib. Cells from each line were left untreated or were treated with vehicle (DMSO), 5 nM cetuximab, or 0.5 μM gefitinib in a medium containing 0.5% FBS. After 16 hours of treatment, the cells were harvested and lysed for quantitative apoptosis measurement by (a) an enzyme-linked immunosorbent assay, as described in the Methods section, and (b) Western blot analysis with anti-PARP antibodies. *P < 0.05, **P < 0.01 compared with corresponding controls.

Back to article page